Structure Therapeutics Inc. (GPCR) stock
Close on Nov 11, 2026Market cap $1.49BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.49B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.22
- Dividend yield
- –
- Free cash flow yield
- -18.56%
Fundamentals
- Net income
- -$293.88M
- EPS, diluted
- -$1.33
- Free cash flow
- -$277.28M
- Book value per share
- $5.59
- Diluted shares
- 219M
Trading
- Next earnings
- Feb 25, 2027 (estimated, during market hours)
- Previous close
- $21.73
- Open
- $21.79
- Day's range
- $20.78 – $21.99
- Volume
- 1,002,761
- Average volume (20 days)
- 1,004,597
- Beta (5 years)
- 1.19
- 52-week range
- $18.70 – $94.90
- RSI (14 days)
- 35.8
- Volatility (1 year)
- 118.9%
- Relative volume
- 1.02×
- WACC
- 10.8%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | GPCR | S&P 500 | Difference | GPCR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.0% | -2.4% | −15.6 pts | ||
| 3 months | -59.8% | -1.2% | −58.7 pts | ||
| Year to date | -69.9% | +12.3% | −82.2 pts | ||
| 1 year | -39.9% | +12.4% | −52.4 pts | ||
| 3 years | -61.8% | +78.8% | −140.6 pts | -27.5% | +21.4% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Structure Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Update
About Structure Therapeutics
Pharmaceutical Preparations
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral small molecule therapeutics for chronic diseases with unmet medical need. Utilizing a structure-based drug discovery platform and computational chemistry, the enterprise targets G-protein coupled receptors across metabolic, cardiovascular, and pulmonary conditions. Its lead product candidate is aleniglipron (GSBR-1290), an oral GLP-1 receptor agonist in clinical trials for obesity and overweight management. The company is also advancing oral small molecule amylin receptor agonists, including ACCG-2671 and ACCG-3535, alongside discovery-stage programs targeting GIP, glucagon, and APJ receptors for use as monotherapies or fixed-dose combinations for individuals living with metabolic and chronic disorders.
Company profile, executives and historyStructure Therapeutics stock: common questions
What is Structure Therapeutics's stock price?
GPCR closed at $20.95 on Nov 11, 2026, down 3.59% on the day. Over the past 52 weeks it traded between $18.70 and $94.90.
What is Structure Therapeutics's market cap?
Structure Therapeutics was worth $1.49B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is GPCR's P/E ratio?
Structure Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.33), so it has no meaningful P/E ratio.
Does Structure Therapeutics pay a dividend?
No. Structure Therapeutics has not paid a cash dividend over the last twelve months.
When does Structure Therapeutics report earnings next?
Structure Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has GPCR stock performed over the past year?
Including dividends, GPCR returned -39.9% over the past year, against +12.4% for the S&P 500.
Who are Structure Therapeutics's competitors?
Companies most similar to Structure Therapeutics by business, industry and size include SKYE, MTVA, VTVT, SEPN, BMEA.
See a number that looks wrong?